| Pfizer's kidney cancer drug to be reviewed by FDA - Proactive Investors USA Canada |
|
|
Proactive Investors USA & Canada The drug, which is designed for previously treated patients with advanced renal cell carcinoma (RCC), an advanced type of kidney cancer, was submitted for review after Pfizer reported positive results from its phase three clinical trial in May. ... Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced |